ARGX-119
- Generic Name
- ARGX-119
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK).
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- argenx
- Target Recruit Count
- 60
- Registration Number
- NCT06441682
- Locations
- 🇩🇰
Bispebjerg University Hospital, Kopenhagen, Denmark
🇸🇪Akademiskt specialistcentrum Karolinska Institutet, Stockholm, Sweden
🇧🇪UZ Leuven, Leuven, Belgium
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- argenx
- Target Recruit Count
- 15
- Registration Number
- NCT06436742
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇫🇷CHU - Hospital de la Timone, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath